Abstract:Background: Nonsmall-cell lung cancer (NSCLC) is one of the most common malignant tumors, and the current drugs have not achieved ideal therapeutic effects. The abnormal activation of STAT3 and FAK signal transduction in tumor cells is highly correlated with their proliferation and migration ability. Therefore, bioactive compounds that can inhibit STAT3 and FAK activation have the potential to become agents to treat NSCLC. Purpose: This study aims to discover new antitumor compounds from Garcinia xipshuanbannaensis and investigate the molecular mechanism by which they inhibit lung cancer proliferation and metastasis in vivo and in vitro, all of which may lead to obtainment of a potential antitumor agent. Methods: Xipsxanthone H was obtained by various chromatography methods (including silica gel, medium pressure liquid chromatography (MPLC), and preparative high-performance liquid chromatography (HPLC)). 1D and 2D nuclear magnetic resonance (NMR) spectra were used to analyze the structure. Cell viability and wound healing assays were employed to detect changes in the proliferation and migration of cancer cells. Cell cycle and apoptosis were analyzed by flow cytometry. The protein expression of STAT3 and FAK signaling pathways affected by xipsxanthone H was determined by Western blotting. The zebrafish model was used to evaluate the in vivo effects of xipshantone H on tumor proliferation and metastasis. Molecular docking was utilized to explore the interaction between xipsxanthone H and STAT3. Cellular thermal shift assays (CETSAs) were employed to explore the possible target of xipsxanthone H. Results: The novel compound xipsxanthone H was purified and characterized from G. xipshuanbannaensis. Xipsxanthone H exhibited strong anti-proliferation activity in a variety of tumor cell lines. In addition to inducing reactive oxygen species (ROS) production and arresting the cell cycle, mechanistic studies demonstrated that xipsxanthone H suppressed STAT3 and FAK phosphorylation and regulated the downstream protein expression of the STAT3 and FAK signaling pathways. The in vivo studies using the zebrafish model revealed that xipsxanthone H inhibited tumor proliferation, metastasis, and angiogenesis. Conclusions: A new xanthone was obtained from G. xipshuanbannaensis, and this compound had the property of inhibiting tumor proliferation and metastasis by targeting STAT3 and FAK signaling pathways in NSCLC. These findings suggested that xipsxanthone H might be a potential candidate agent for NSCLC treatment.

Xanthohumol Targets the ERK1/2‑Fra1 Signaling Axis to Reduce Cyclin D1 Expression and Inhibit Non‑small Cell Lung Cancer

Xanthohumol Inhibits Non‐small Cell Lung Cancer Via Directly Targeting T‐lymphokine‐activated Killer Cell‐originated Protein Kinase

Xanthotoxol Suppresses Non-Small Cell Lung Cancer Progression and Might Improve Patients’ Prognosis

Xanthohumol Inhibits Colorectal Cancer Cells Via Downregulation Of Hexokinases Ii-Mediated Glycolysis

Xanthohumol Inhibits Proliferation of Laryngeal Squamous Cell Carcinoma.

Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo

Xanthohumol Promotes Skp2 Ubiquitination Leading to the Inhibition of Glycolysis and Tumorigenesis in Ovarian Cancer

Xanthohumol inhibits proliferation in lymphoma cells by generation of reactive oxygen species and G 0 / G 1-phase cell cycle arrest

Xanthorrhizol Inhibits Non‐small Cell Carcinoma (A549) Cell Growth and Promotes Apoptosis Through Modulation of PI3K/AKT and NF‐κB Signaling Pathway

Inhibition of Breast Cancer Cell Survival by Xanthohumol Via Modulation of the Notch Signaling Pathway in Vivo and in Vitro

A Natural Xanthone Suppresses Lung Cancer Growth and Metastasis by Targeting STAT3 and FAK Signaling Pathways

Cratoxylumxanthone C, a Natural Xanthone, Inhibits Lung Cancer Proliferation and Metastasis by Regulating STAT3 and FAK Signal Pathways.

Xanthine negatively regulates c‐MYC through the PI3K/AKT signaling pathway and inhibits the proliferation, invasion, and migration of breast cancer cells

ERO1L promotes NSCLC development by modulating cell cycle‐related molecules

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover

Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer

SNX-2112 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Non-Small Cell Lung Cancer by Downregulating Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Signaling Pathway

Farnesoid X Receptor, a Novel Proto-Oncogene in Non-Small Cell Lung Cancer, Promotes Tumor Growth Via Directly Transactivating CCND1

Xanthatin inhibits non-small cell lung cancer proliferation by breaking the redox balance

Xanthohumol induces paraptosis of leukemia cells through p38 mitogen activated protein kinase signaling pathway.

Xanthohumol hinders invasion and cell cycle progression in cancer cells through targeting MMP2, MMP9, FAK and P53 genes in three-dimensional breast and lung cancer cells culture